Three, multicentre, large‐scale, randomized, placebo‐controlled trials of cardiovascular outcomes with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors have each shown substantial reductions in rates of hospitalization for heart failure and progression of chronic kidney disease in people with t…